[GLUTAMIC-OXALACETIC TRANSAMINASE AND GLUTAMIC-PYRUVIC TRANSAMINASE IN TYPHOID PATIENTS TREATED WITH 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYLPROPIONATE IN THE COURSE OF CHLORAMPHENICOL-PREDNISONE THERAPY].
D000293:Adolescent; D000410:Alanine Transaminase; D045930:Anabolic Agents; D001219:Aspartate Aminotransferases; D002701:Chloramphenicol; D004796:Clinical Enzyme Tests; D051263:D-Alanine Transaminase; D004358:Drug Therapy; D009277:Nandrolone; D011241:Prednisone; D013256:Steroids; D000637:Transaminases; D014435:Typhoid Fever; D014436:Typhoid-Paratyphoid Vaccines
D045930:Anabolic Agents; D013256:Steroids; D014436:Typhoid-Paratyphoid Vaccines; D002701:Chloramphenicol; D009277:Nandrolone; D000637:Transaminases; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D051263:D-Alanine Transaminase; D011241:Prednisone
ADOLESCENCE; ALANINE AMINOTRANSFERASE; ANABOLIC STEROIDS; ASPARTATE AMINOTRANSFERASE; CHLORAMPHENICOL; DRUG THERAPY; ENZYME TESTS; PREDNISONE; TYPHOID
TRANSAMINASI GLUTAMMICO-OSSALACETICA E GLUTAMMICO-PIRUVICA IN TIFOSI TRATTATI CON 4-IDROSSI-19-NORTESTOSTERONE-17-CICLOPENTILPROPIONATO NEL CORSO DELLA TERAPIA CAF-PREDNISCONICA.